425 filed Aug 17, 2026 at 08:31 ET
Fulcrum Therapeutics (FULC) and Slate Medicines announced a definitive merger agreement in which Fulcrum will acquire Slate in an all-stock reverse merger. Fulcrum is valued at $31.3M and Slate at $350M, with a concurrent $245M PIPE led by Frazier Life Sciences. Pre-merger FULC stockholders will receive a special cash dividend of approximately $270M (subject to adjustment) and will own ~5% of the combined company, which will be renamed Slate Medicines and trade under the ticker SLTE. The deal is expected to close in Q4 2026.